+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: 293T cells, Primary antibody: P07045(IL11RA Antibody) at dilution 1/250, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 minute    

  
  

The interleukin-11 receptor alpha (IL11RA) is a key subunit of the interleukin-11 (IL-11) receptor complex, which mediates signaling of the IL-11 cytokine, a member of the IL-6 family. IL-11 signaling plays diverse roles in tissue homeostasis, inflammation, and cancer progression by activating pathways such as JAK/STAT, MAPK, and PI3K/AKT. IL11RA binds IL-11. enabling recruitment of the shared GP130 co-receptor to trigger downstream signaling. Dysregulation of IL-11/IL11RA signaling is implicated in fibrotic diseases, autoimmune disorders, and tumorigenesis, particularly in cancers of the colon, stomach, and breast, where it promotes metastasis and chemoresistance.

IL11RA-targeting antibodies are tools for research and therapeutic development. In research, they help map IL-11 signaling mechanisms, detect receptor expression in tissues, or block IL-11 interactions to study pathway effects. Therapeutically, neutralizing anti-IL11RA antibodies aim to inhibit aberrant IL-11 signaling in diseases like fibrosis or cancer. Preclinical studies suggest that blocking IL11RA may reduce inflammation, fibrosis, and tumor growth. However, challenges remain in optimizing specificity and minimizing off-target effects. Recent advances include humanized monoclonal antibodies and bispecific designs, with some candidates entering early clinical trials. Understanding IL11RA's structure and tissue-specific roles remains critical for refining antibody-based strategies.